Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly stock was falling early Thursday even as the drugmaker posted first-quarter earnings that beat analysts’ expectations. This is breaking news. Read a preview of Eli Lilly below and check back ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly stock (NYSE: LLY) stock is showing positive momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a ...

The stock's reaction suggested that investors ... Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free. Eli Lilly’s shares are not very volatile and have only ...

On this episode of Stock Movers: - Apple (APPL ... Apple didn’t respond to Bloomberg’s request for comment. - Eli Lilly (LLY) are up in after hours trading. Earlier today, President Donald ...

Financial analysis suggests Lilly is reasonably ... will compete with Eli Lilly’s offerings. Finally, Eli Lilly’s stock is priced for significant optimism regarding its growth prospects ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Eli Lilly? Access our full analysis report here ...